Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Renaissance Pharma Inc.

Division of Renaissance Acquisition Holdings LLC
www.renaissancepharmainc.com

Latest From Renaissance Pharma Inc.

Appointments: Astellas, BIO, Hikma, Eton, Akili and Oxford BioDynamics

This week's roundup includes CEO appointments by Eton Pharmaceuticals, the Biotechnology Innovation Organization and Hikma, in addition to various other high-level appointments by Astellas, Akili Interactive Labs and Oxford BioDynamics.

BioPharmaceutical Appointments

Generic Manufacturers Try To Up Their Game As US Pressure Persists

With US generic drug price erosion running at double digits, 2017 is expected to be a challenging year for the generic drug sector. Manufacturers are looking increasingly to complex generics, injectables and biosimilars as an offset, but it's unclear if wins in those areas will be enough to bridge the growth divide.

Generic Drugs Business Strategies

Mylan Revamp Sees India R&D Layoffs; More In Store?

Mylan has handed pink slips to around 50 personnel at its Indian R&D unit as it pursues a global revamp aimed at streamlining operations and reining in costs following multiple acquisitions over the past few years.

Commercial India

Mylan’s Growth Strategy: Diversification, Expansion And R&D Investment

The generic drug company will drive mid-term growth by investing in high-barrier-to-entry generics and biosimilars while diversifying into brand medicines and over-the-counter drugs. Management presented a strategy overview during an investor day March 1.

Biosimilars Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Renaissance Acquisition Holdings LLC
  • Senior Management
  • Patrick D McIntosh, VP, Commerical Operations
    Louis J Pearce, Dir., Fin.
    John W Denman, General Manager
    Greg Besase, VP, Branded Products
    Soby M Fennell, Dir, Reg Affairs
    Rafal Czapla, Marketing Manager
  • Contact Info
  • Renaissance Pharma Inc.
    Phone: (267) 685-0340
    411 S. State St.
    Ste. E-100
    Newtown, PA 18940
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register